Yayın:
Otoprotective effects of farnesene against oxidative damage induced by paclitaxel

dc.contributor.authorDİNCER, Büşra
dc.contributor.authorATALAY, Fatma
dc.contributor.authorTATAR, Arzu
dc.date.accessioned2026-01-05T22:57:01Z
dc.date.issued2022-06-30
dc.description.abstractPurpose: This study explores the biochemical and functional effects of farnesene, which has potent free radical scavenging and antioxidant properties, on paclitaxel-induced ototoxicity. Materials and Methods: Eighteen male Wistar albino rats were allocated into three groups of six rats at random. No paclitaxel or farnesene was given to the control group throughout the research. Paclitaxel was given four times intraperitoneally at a dose of 5 mg/kg (1st, 7th, 14th & 21st days) in the paclitaxel group. In the Farnesene + Paclitaxel group, 5 mg/kg paclitaxel was given first, followed by 4 times 50 mg/kg farnesene intraperitoneally 30 minutes later (1st, 7th, 14th & 21st days). Otoacoustic emission measurement was taken on days 0 and 21 in all rats. After that, the animals were sacrificed, and their cochleas were extracted for biochemical testing. Results: Paclitaxel caused oxidative stress in the cochlea, which considerably elevated malondialdehyde levels and lowered glutathione levels in cochlear tissues. Furthermore, the paclitaxel group’s distortion product otoacoustic emission values were significantly lower than the other groups. Improvements in the damage produced by paclitaxel in various biochemical and functional parameters were observed in the Farnesene+Paclitaxel group. Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.
dc.description.urihttps://doi.org/10.17826/cumj.1093970
dc.description.urihttps://dergipark.org.tr/tr/pub/cumj/issue/69190/1093970
dc.identifier.doi10.17826/cumj.1093970
dc.identifier.endpage791
dc.identifier.issn2602-3032
dc.identifier.openairedoi_dedup___::3f278728345277655d0fb14b7b57f5f8
dc.identifier.orcid0000-0002-3365-7741
dc.identifier.orcid0000-0002-0344-1982
dc.identifier.orcid0000-0002-4486-2695
dc.identifier.startpage783
dc.identifier.urihttps://hdl.handle.net/20.500.12597/43469
dc.identifier.volume47
dc.identifier.wos000815481700036
dc.publisherCukurova Medical Journal
dc.relation.ispartofCukurova Medical Journal
dc.rightsOPEN
dc.subjectAntioksidanlar
dc.subjectFarnesen
dc.subjectOtoakustik emisyon
dc.subjectOtotoksisite
dc.subjectPaklitaksel
dc.subjectKlinik Tıp Bilimleri
dc.subjectClinical Sciences
dc.subjectAntioxidants
dc.subjectFarnesene
dc.subjectOtoacoustic emission
dc.subjectOtotoxicity
dc.subjectPaclitaxel
dc.subjectOtotoxicity
dc.subject.sdg3. Good health
dc.titleOtoprotective effects of farnesene against oxidative damage induced by paclitaxel
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Büşra DİNCER","name":"Büşra","surname":"DİNCER","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-3365-7741"},"provenance":null}},{"fullName":"Fatma ATALAY","name":"Fatma","surname":"ATALAY","rank":2,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0002-0344-1982"},"provenance":null}},{"fullName":"Arzu TATAR","name":"Arzu","surname":"TATAR","rank":3,"pid":{"id":{"scheme":"orcid_pending","value":"0000-0002-4486-2695"},"provenance":null}}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"und","label":"Undetermined"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Antioksidanlar;Farnesen;Otoakustik emisyon;Ototoksisite;Paklitaksel"},"provenance":null},{"subject":{"scheme":"keyword","value":"Klinik Tıp Bilimleri"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Clinical Sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antioxidants;Farnesene;Otoacoustic emission;Ototoxicity; Paclitaxel;Ototoxicity"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Otoprotective effects of farnesene against oxidative damage induced by paclitaxel","subTitle":null,"descriptions":["<jats:p xml:lang=\"en\">Purpose: This study explores the biochemical and functional effects of farnesene, which has potent free radical scavenging and antioxidant properties, on paclitaxel-induced ototoxicity. Materials and Methods: Eighteen male Wistar albino rats were allocated into three groups of six rats at random. No paclitaxel or farnesene was given to the control group throughout the research. Paclitaxel was given four times intraperitoneally at a dose of 5 mg/kg (1st, 7th, 14th &amp;amp; 21st days) in the paclitaxel group. In the Farnesene + Paclitaxel group, 5 mg/kg paclitaxel was given first, followed by 4 times 50 mg/kg farnesene intraperitoneally 30 minutes later (1st, 7th, 14th &amp;amp; 21st days). Otoacoustic emission measurement was taken on days 0 and 21 in all rats. After that, the animals were sacrificed, and their cochleas were extracted for biochemical testing. Results: Paclitaxel caused oxidative stress in the cochlea, which considerably elevated malondialdehyde levels and lowered glutathione levels in cochlear tissues. Furthermore, the paclitaxel group’s distortion product otoacoustic emission values were significantly lower than the other groups. Improvements in the damage produced by paclitaxel in various biochemical and functional parameters were observed in the Farnesene+Paclitaxel group. Conclusion: The study findings imply that farnesene, a natural antioxidant, reduced paclitaxel-induced hearing loss in rats, and a combination of farnesene and paclitaxel therapy may have protected from paclitaxel-induced ototoxicity for future clinical use.</jats:p>"],"publicationDate":"2022-06-30","publisher":"Cukurova Medical Journal","embargoEndDate":null,"sources":["Crossref","Volume: 47, Issue: 2 783-791","2602-3032","2602-3040","Cukurova Medical Journal"],"formats":["application/pdf"],"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Cukurova Medical Journal","issnPrinted":"2602-3032","issnOnline":null,"issnLinking":null,"ep":"791","iss":null,"sp":"783","vol":"47","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::3f278728345277655d0fb14b7b57f5f8","originalIds":["10.17826/cumj.1093970","50|doiboost____|3f278728345277655d0fb14b7b57f5f8","50|tubitakulakb::2c9d222c3d58d57bb896f5af88c77329","oai:dergipark.org.tr:article/1093970"],"pids":[{"scheme":"doi","value":"10.17826/cumj.1093970"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":1,"influence":2.5441678e-9,"popularity":2.627616e-9,"impulse":1,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C5"}},"instances":[{"pids":[{"scheme":"doi","value":"10.17826/cumj.1093970"}],"type":"Article","urls":["https://doi.org/10.17826/cumj.1093970"],"publicationDate":"2022-06-30","refereed":"peerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.17826/cumj.1093970"}],"type":"Article","urls":["https://dergipark.org.tr/tr/pub/cumj/issue/69190/1093970"],"publicationDate":"2022-03-27","refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS

Dosyalar

Koleksiyonlar